Navigation Links
Lightlake Therapeutics Inc. Chief Executive Officer Letter to Shareholders
Date:12/20/2013

LONDON, Dec. 20, 2013 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake" or the "Company") (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, today issued a letter by Chief Executive Officer Dr. Roger Crystal updating shareholders on the Company's progress in 2013.

Dear Fellow Shareholders,

As the executive management team of Lightlake Therapeutics Inc. looks ahead to 2014, we are encouraged by our hard work and progress in 2013 and are eager for the opportunities and advancements that 2014 should bring to our company. This has been a fruitful year for the Company as we have achieved a number of milestones, both operationally and clinically.  We continue to work diligently to advance our clinical pipeline and secure our patent portfolio as we focus on bringing an intranasal naloxone treatment to market to reverse opioid overdoses.

Since our last update in April 2013, we would like to highlight a few of our accomplishments.  We recently completed a two-week joint clinical study with the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), for opioid overdose.  We received the initial data from this study and it has shown that our naloxone nasal spray can potentially be delivered into the blood stream at least as quickly as the injection process currently used by hospitals, first responders, and others treating opioid overdoses.

The data received from this study will also allow us to apply our novel method of naloxone delivery into a wider range of various addictions that are currently affecting millions of people on a daily basis.  While opioid overdose is a significant, near-term opportunity that can potentially be treated with an intranasal naloxone application, there are a number of other markets that our application could potentially be app
'/>"/>

SOURCE Lightlake Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lightlake Therapeutics Commences Two-Week Patient Trial for Treatment of Opioid Overdose with National Institute on Drug Abuse (NIDA)
2. Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
3. Moderna Therapeutics Appoints Theo Melas-Kyriazi to Board of Directors
4. Abeona Therapeutics Closes $750,000 in Seed Round to Develop Therapies for Children Suffering from Rare Sanfilippo Diseases
5. BiOptix Continues Support of Antibody Engineering & Therapeutics Research
6. NKT Therapeutics Identifies Novel anti-iNKT Antibodies for Depleting or Activating iNKT Cells
7. Northwest Biotherapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
8. Orexigen Therapeutics, Inc. Prices Offering of $100 Million of Convertible Senior Notes
9. Intarcia Therapeutics Appoints Nancy Thornberry to Board of Directors
10. Scientists develop way to successfully give nanoparticle therapeutics orally
11. Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Dose-Ranging Field Study in Client-Owned Dogs with Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research ( http://www.bccresearch.com ) reveals in its new report, ... MARKETS , the global market for digital polymerase chain ... This is estimated to grow to $490 billion in ... of 28.6%. , New digital PCR technology has created ... broader PCR field. The opportunities presented by this technology ...
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Cayenne ... company specializing in the soft tissue reconstruction segment, ... Anchor System for surgeries involving the shoulder and ... through a novel, inserter-controlled deployment method. The unique ... partial deployment, anchor pull-out, or anchor displacement (also ...
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2
... NWBS and NWBT; OTC Bulletin Board: NWBO) (the,"Company") announces ... Holdings,through the subscription of 1,000,000 new shares in the ... The new stock is expected to be admitted ... will not be tradable on the,Company,s OTC bulletin board ...
... (TSX-V: ICO) is pleased to announce the completion of ... company with sufficient capital to develop iCo-007 through to ... is targeting the treatment of Diabetic Macular Edema. The ... working capital. iCo,s partner Isis Pharmaceuticals Inc., (NASDAQ: ...
... Technologies (Celsis,IVT), a division of Celsis International plc, ... and Wisconsin-based Promega Corp,will take the trial and ... Celsis IVT is pre-qualifying lots of its extensive ... including,the P450-Glo(TM) CYP Assay used to study cytochrome ...
Cached Biology Technology:Northwest Biotherapeutics Secures $700,000 Equity Financing 2iCo Therapeutics Closes $1.3 Million Private Placement 2iCo Therapeutics Closes $1.3 Million Private Placement 3Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes 2Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes 3
(Date:7/11/2014)... 2014---A team of researchers from The Chinese University of ... gene of wild soybean linked to salt tolerance, with ... saline soil. This study published online in Nature ... genomic information for crop improvement. , Soybean is an ... human selection, cultivated soybeans have less genetic diversities than ...
(Date:7/11/2014)... Social animals often develop relationships with other group members ... In wild chacma baboons the strategy for grooming activities ... are just published in the scientific journal Biology ... of baboons is not practiced without ulterior motives. To ... for the individual, while grooming another individual can provide ...
(Date:7/11/2014)... from Ume University, Sweden, have explored two different ... reaction sequence leading to the formation of oxygen ... published in the scientific journal Nature Communications ... present day synthetic catalysts for water oxidation, which ... for the direct storage of solar energy in ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2Baboons groom early in the day to get benefits later 2Molecular snapshots of oxygen formation in photosynthesis 2
... of 70 scientists from the U.S., China, Australia and Japan ... "sacred lotus," which is believed to have a powerful genetic ... aging successfully. The scientists sequenced more than 86 percent of ... , which is revered in China and elsewhere as a ...
... 2013 In a groundbreaking move that provides new insight ... University have successfully sequenced the complete genome of a Scarlet ... by Drs. Christopher Seabury and Ian Tizard at the Schubot ... & Biomedical Sciences at Texas A&M. Their work is published ...
... in Nature , researchers at NYU School of ... tumor cells feed themselves, opening up new therapeutic possibilities ... Pancreatic cancer kills nearly 38,000 Americans annually, making it ... for most people diagnosed with it is less than ...
Cached Biology News:Scientists sequence genome of 'sacred lotus,' which likely holds anti-aging secrets 2Scientists sequence genome of 'sacred lotus,' which likely holds anti-aging secrets 3Scientists sequence genome of 'sacred lotus,' which likely holds anti-aging secrets 4Saving the parrots: Texas A&M team sequences genome of endangered macaw birds 2Breakthrough in how pancreatic cancer cells ingest nutrients points to new drug target 2
...
...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Chicken polyclonal to QPRT ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to Internal sequence amino acids 123-237 of Human QPRT Entrez Gene ID: 23475 ...
Biology Products: